Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 1
2018 4
2019 7
2020 11
2021 12
2022 13
2023 7
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Results by year

Filters applied: . Clear all
Page 1
Strategy.
Trillsch F, Reichenbach J, Czogalla B, Kraus F, Burges A, Mahner S, Kessler M. Trillsch F, et al. Among authors: czogalla b. J Vis Exp. 2024 Feb 23;(204). doi: 10.3791/66467. J Vis Exp. 2024. PMID: 38465946
Editorial: Endocrine aspects of gynaecological cancers.
Czogalla B, Montt-Guevara MM, Jeschke U. Czogalla B, et al. Front Endocrinol (Lausanne). 2024 Feb 9;15:1377378. doi: 10.3389/fendo.2024.1377378. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38405147 Free PMC article. No abstract available.
Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center.
Kraus FBT, Sultova E, Heinrich K, Jung A, Westphalen CB, Tauber CV, Kumbrink J, Rudelius M, Klauschen F, Greif PA, König A, Chelariu-Raicu A, Czogalla B, Burges A, Mahner S, Wuerstlein R, Trillsch F. Kraus FBT, et al. Among authors: czogalla b. Int J Mol Sci. 2024 Feb 16;25(4):2345. doi: 10.3390/ijms25042345. Int J Mol Sci. 2024. PMID: 38397025 Free PMC article.
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial.
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, Lindemann K, Woelber L, Colombo N, Duska L, Leary A, Godoy-Ortiz A, Nishio S, Angelergues A, Rubio MJ, Fariñas-Madrid L, Yamaguchi S, Lorusso D, Ray-Coquard I, Manso L, Joly F, Alarcón J, Follana P, Romero I, Lebreton C, Pérez-Fidalgo JA, Yunokawa M, Dahlstrand H, D'Hondt V, Randall LM; ENGOT-Cx10–GEICO 68-C–JGOG1084–GOG-3030 Investigators. Oaknin A, et al. Lancet. 2024 Jan 6;403(10421):31-43. doi: 10.1016/S0140-6736(23)02405-4. Epub 2023 Dec 1. Lancet. 2024. PMID: 38048793 Clinical Trial.
Nuclear receptor co-repressor NCOR2 and its relation to GPER with prognostic impact in ovarian cancer.
Reichenbach J, Fraungruber P, Mayr D, Buschmann C, Kraus FBT, Topalov NE, Chelariu-Raicu A, Kolben T, Burges A, Mahner S, Kessler M, Jeschke U, Czogalla B, Trillsch F. Reichenbach J, et al. Among authors: czogalla b. J Cancer Res Clin Oncol. 2023 Sep;149(11):8719-8728. doi: 10.1007/s00432-023-04708-z. Epub 2023 May 2. J Cancer Res Clin Oncol. 2023. PMID: 37131060 Free PMC article.
Treatment and survival of patients with malignant ovarian sex cord-stromal cell tumours: An analysis of the Arbeitsgemeinschaft für Gynäkologische Onkologie (AGO) study group CORSETT database.
Klar M, Plett H, Harter P, Heitz F, Kommoss S, Hartkopf AD, Grube M, Roser E, Sehouli J, Braicu I, Czogalla B, Burges A, Bossart M, Hasanov MF, Link T, Staebler A, Mayr D, Buderath P, Hasenburg A. Klar M, et al. Among authors: czogalla b. J Surg Oncol. 2023 Jul;128(1):111-118. doi: 10.1002/jso.27248. Epub 2023 Mar 28. J Surg Oncol. 2023. PMID: 36975108 Review.
56 results